# Open Targets Platform 22.02 has been released!

**URL:** https://community.opentargets.org/t/open-targets-platform-22-02-has-been-released/476
**Category:** Releases
**Created:** [1 March 2022 11:19 UTC](https://community.opentargets.org/t/open-targets-platform-22-02-has-been-released/476 "2022-03-01T11:19:43Z")
**Posts on this page:** 1
**Page:** 1

<div class="post-metadata">

### Author: ![hcornu](https://dub1.discourse-cdn.com/flex017/user_avatar/community.opentargets.org/hcornu/32/716_2.png) [@hcornu](https://community.opentargets.org/u/hcornu)
#### Post date: [1 March 2022 11:19 UTC](https://community.opentargets.org/t/open-targets-platform-22-02-has-been-released/476/1 "2022-03-01T11:19:43Z")

</div>

We have just released the latest data update to the Open Targets Platform — 22.02.

## Key highlights for this release:

- Gene2Phenotype has updated their terminology, in line with the terms established by the Gene Curation Coalition (GenCC). This is reflected in the Platform.
- We have integrated new data from several providers, in particular the OT Genetics portal and ChEMBL.
- The Open Targets COVID-19 target prioritisation tool has been deprecated, but the data is available in the Open Targets Platform.

This release integrates 10,880,832 evidence strings to build 7,980,448 target-disease associations between 18,468 diseases and 61,524 targets from the following 22 public resources:

- 1,112,480 genetic evidence from [European Variation Archive (EVA)](http://www.ebi.ac.uk/eva/)
- 693,583 genetic evidence from [Open Targets Genetics Portal](https://genetics.opentargets.org/)
- 3,159 genetic evidence from [Gene2Phenotype](https://www.ebi.ac.uk/gene2phenotype)
- 25,109 genetic evidence from the[Genomics England PanelApp](https://bioinfo.extge.co.uk/crowdsourcing/PanelApp/)
- 1,574 genetic evidence from [ClinGen](https://search.clinicalgenome.org/kb/gene-validity/)
- 5,989 genetic evidence from Orphanet
- 171,390 genetic evidence from the[PheWAS catalog](https://phewascatalog.org/)
- 5,160 genetic evidence from [UniProt Literature](https://www.uniprot.org/)
- 11,547 somatic evidence from [European Variation Archive (EVA)](http://www.ebi.ac.uk/eva/)
- 3,299 somatic evidence from[intOGen](https://www.intogen.org/)
- 74,159 somatic evidence from the[Cancer Gene Census](http://cancer.sanger.ac.uk/census/)
- 33,906 somatic evidence from [Uniprot](http://www.uniprot.org/)
- 560,562 drug evidence from [ChEMBL](https://www.ebi.ac.uk/chembl/)
- 231,165 expression evidence from [Expression Atlas](https://www.ebi.ac.uk/gxa/home)
- 9,943 affected pathway evidence from [Reactome](https://reactome.org/)
- 72,370 affected pathway evidence from [SLAPenrich](https://saezlab.github.io/SLAPenrich/)
- 378 affected pathway evidence from [PROGENy](https://saezlab.github.io/progeny/)
- 389 systems biology evidence from [SysBio](https://saezlab.github.io/progeny/)
- 1,299 somatic evidence from the [Cancer Genome Interpreter](https://www.cancergenomeinterpreter.org/home)
- 1,828 CRISPR-Cas9 (Cancer Cell Lines) evidence from[Behan et al. 2019](https://europepmc.org/abstract/MED/30971826)
- 1,180,496 mouse model evidence from[PhenoDigm](https://www.sanger.ac.uk/resources/databases/phenodigm)
- 6,681,037 scientific literature evidence from co-occurence mining in [Europe PMC](https://europepmc.org/)

Additionally, the Platform now allows users to explore data on 12,594 drugs.

For more details, read [the 22.02 release blog post](https://blog.opentargets.org/open-targets-platform-22-02-release/).